Drug Trial Radar · NCT07639931
Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and Application
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
3,035
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Dec 20, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Tibet Autonomous Region People's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 10, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to establish a key technical system for the diagnosis and treatment of severe acute mountain sickness based on real-world clinical data in Xizang, develop standardized diagnosis and treatment protocols and an intelligent early warning model, validate its efficacy through multicenter studies, and innovate diagnostic and therapeutic technologies. It will achieve early identification, precise diagnosis, standardized treatment, and intelligent warning of severe acute mountain sickness, comprehensively improving its prevention, control and treatment success rate.
Conditions
- Severe High Altitude Pulmonary Edema
- Severe High Altitude Cerebral Edema
Interventions
Multicenter study of HAPE:CPAP or BiPAP GroupDevice
Traditional treatment plus CPAP or BiPAP
Multicenter study of HAPE group:NO GroupDrug
Traditional treatment plus inhaled nitric oxide therapy (20-40 ppm, continuous administration for 12-24 hours)
Protocol for Proteomics and Peptidomics Study of HAPE:Case GroupOther
40 patients clinically diagnosed with HAPE. Peripheral venous blood samples were collected during the acute onset stage and prior to any effective intervention.
Primary outcomes
What the sponsor says the trial is designed to measure.
- HAPE:RecoveryTime frame: From date of disease onset to achievement of recovery criteria ,assessed up to 36 months
- HACE :recoveryTime frame: From date of disease onset to achievement of recovery criteria ,assessed up to 36 months
- DeathTime frame: From admission to discharge, or all-cause mortality within 30 days and 90 days after discharge.
- Length of hospital stayTime frame: The total duration from the first day of hospitalization to recovery and discharge, assessed up to 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xizang Autonomous Region People's Hospital
Lhasa, Tibet, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.